$XAIR

Beyond Air, Inc. (XAIR): Entry into a Material Definitive Agreement

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. The description in Item 5.02 below, as it relates to the terms and conditions of the Employment Agreement with Mr. Goodman, a copy of which is filed herewith as Exhibit 10.1, is incorporated herein by reference. Item 5.02. Dep

Original reporting
Published Sep 24, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$XAIR
Neutral
medium confidence
Mentioned
$XAIR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$XAIRNeutralLow
01

Why it matters

The filing is a routine corporate governance disclosure with limited market impact.

02

Market read

Primary disclosure of executive compensation; low trading relevance.

03

What to watch

Potential upcoming financing rounds may make compensation terms more material if dilution occurs.

Relevance 6/10Novelty 5/10Timing: filed Sep 24 2026

Background

Beyond Air is a micro‑cap aerospace company that recently appointed its CEO and adjusted CFO compensation.

Company-level read

Ticker impact

$XAIRNeutralMedium confidence
Context

Beyond Air disclosed a new employment agreement for CEO Robert Goodman with a $650,000 base salary and a CFO salary increase to $463,000.

Expected impact

minimal impact, potential slight upside if investors view leadership stability positively

Evidence & confidence

Compensation disclosures are routine; the amounts are modest relative to market cap, so price reaction is expected to be limited.

Market effects

Limited; executive pay updates do not materially affect the broader aerospace/defense sector.

None; the filing pertains only to Beyond Air's internal matters.

Low; no cross‑border implications.

Counterpoint

Investors could view the higher executive pay as a red flag for cash burn in a cash‑intensive startup.

Key entities

  • Robert Goodman

    Newly appointed CEO with a $650k base salary.

  • Daniel Moorhead

    CFO whose base salary was increased to $463k.

Related articles

$XAIRMed

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement fo

$XAIRMed

Beyond Air, Inc. Q1 2027 Earnings Call Summary

Beyond Air, Inc. reported Q1 2027 revenue of $1.8 million, citing long hospital contracting cycles. Management said its sales pipeline doubled and secured a national GPO agreement. It reaffirmed 2026 revenue guidance of $8 million and projected 2027 revenue of $16-$18 million, tied to Gen II LungFit PH FDA timing. A $30 million financing supports Gen II launch.

$XAIRMed

Beyond Air (XAIR) Q1 2027 Earnings Call Transcript

Beyond Air (XAIR) held a Q1 2027 earnings call. It reported Q ended June 30, 2026 revenue of $1.8 million, flat vs the prior quarter, with gross margin rising to 13% from 9%. The company reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million, pending FDA approval for its Gen II LungFit PH system. It also entered a national GPO deal and announced financing up to $30 million.

$XAIRMedAI 8/10

Beyond Air Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

Beyond Air (NASDAQ: XAIR) reported Q2 2026 revenue of $1.8 million and gross margin of 13%. It reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16-$18 million, including second-generation LungFit PH revenue pending FDA approval. The company is awaiting FDA review of a PMA supplement, expects a decision in 2H 2026, and raised up to $30.1 million.

$XAIRMedAI 8/10

Beyond Air (XAIR) Q4 2026 Earnings Call Transcript

Beyond Air (XAIR) reported fiscal 2026 revenue of $7.7 million (+107%) and Q4 revenue of $1.9 million (+66%). Management cited ~90% customer renewal and expects CY 2026 revenue guidance of $8 million and CY 2027 of $16–$18 million. Gross profit was $0.3 million vs a prior-year loss; net loss was $33.2 million. The company also approved a 1-for-20 reverse stock split and guided on Gen 2 regulatory approval as a key catalyst.